Language selection

Search

Patent 1041013 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1041013
(21) Application Number: 221248
(54) English Title: APPETITE CURBING PREPARATION CONTAINING AN ALGINATE AND A DIPHOSPHONIC ACID
(54) French Title: MODERATEUR DE L'APPETIT CONTENANT UN ALGINATE ET DE L'ACIDE DIPHOSPHORIQUE
Status: Expired
Bibliographic Data
(52) Canadian Patent Classification (CPC):
  • 167/199
(51) International Patent Classification (IPC):
  • A61K 31/715 (2006.01)
  • A23L 1/0532 (2006.01)
  • A23L 1/308 (2006.01)
  • C08L 5/04 (2006.01)
(72) Inventors :
  • HEINE, CHRISTIAN (Not Available)
  • WORMS, KARL-HEINZ (Not Available)
  • BLUM, HELMUT (Not Available)
  • GLOXHUBER, CHRISTIAN (Not Available)
(73) Owners :
  • HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (Not Available)
(71) Applicants :
(74) Agent:
(74) Associate agent:
(45) Issued: 1978-10-24
(22) Filed Date:
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data: None

Abstracts

English Abstract



ABSTRACT OF THE DISCLOSURE
An appetite curbing preparation comprising
an alginate and diphosphonic acid or a nontoxic pharma-
cologically acceptable water-soluble salt thereof as an
inhibitor of the precipitation of calcium salts. This
preparation is useful for curbing the appetite of a warm-
blooded animal.


Claims

Note: Claims are shown in the official language in which they were submitted.



THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. An appetite curbing composition for warm-blooded
animals comprising
(A) an alginic compound selected from the groups
consisting of alginic acid and the nontoxic pharmacologically
acceptable water-soluble salts thereof, and
(B) a substoichiometric amount based on the calcium
required to gel said alginic compound of a diphosphonic compound
having the formula:

Image

wherein R1 is selected from the group consisting of hydrogen
and methyl;and the nontoxic pharmacologically acceptable water-
soluble salts thereof.

2. The appetite curbing composition of Claim 1 wherein
the weight of said diphosphonic compound is 0.5% to 2% of the
weight of said alginic compound.

3. A composition according to Claim 1 wherein R1 is
hydrogen.

4, A composition according to Claim 1 wherein R1 is
methyl.

5. A composition according to Claim 1 wherein the
diphosphonic compound is a 1,1-diphosphonopropane-2.3-
dicarboxylic acid salt.

6. A composition according to Claim 1 in which said
alginic and diphosphonic compounds are present as partial
salts which produce a pH in the range of 6 to 8.5 when dissolved
in water.


7. A composition according to Claim 1 wherein said
salts are selected from the group consisting of the alkali
metal, magnesium, ammonium and loweralkanol ammonium salts,
and mixtures thereof.

8. An appetite curbing composition for a warm-blooded
animal consisting essentially of from 25% to 50% by weight
of the appetite curbing composition of Claim 1, and from
50% to 75% by weight of a nontoxic pharmacologically accept-
able carrier therefor.

9. A composition according to Claim 1 in unit dose
pill form.

10. An aqueous solution containing 0.5% to 5% by weight
of the composition of Claim 8.


Description

Note: Descriptions are shown in the official language in which they were submitted.


1(~4101~
The present invention relates to appetite curbing
compositions for mammals, methods for the preparation of
such compositions, and methods for curbing the appetite of
mammals by use of said compositions.
It is known to produce preparations based on
alignates for use as appetite curbing agents in slimming
diets. Since these preparations swell in the stomach and ~ `
intestinal tract, they produce a feeling of fullness and
satisfaction in human beings. However, the preparations
10 have a considerable disadvantage in that in the presence of
calcium ions they form calcium-containing deposits of low
solubility. As a result, it is possible for a calcium ion
deficiency to be produced, particularly in the intestinal
tract. The fear has therefore often been voiced that dis-
turbances of the metabolism could thereby be produced.
It is an object of the present invention to over-
come the above-described drawbacks of the prior art.
It is another object of the present invention to
proyide A preparation comprising alginic acid and a diphosphonic
20 acid ~or nontoxic pharmacologically acceptable water-soluble
salts thereof~ in which the diphosphonic- acid acts as inhibitor
of the precipitation of calcium salts; and thereby inhibits
precipitation of calcium ions; this preparation is useful for
curbing the appetite of a warm-blooded animal.
These and further objects of the present invention -~
will become apparent as the description thereof proceeds.
The present invention relates to alginic acid pre-
parations containing a diphosphonic acid (or nontoxic pharma-
cologically acceptable water-soluble salts thereof) as inhibitor
30 of the precipitation of calcium salts when the composition is
ingested. This preparation is useful as an appetite curbing
agent for warm-blooded animals.




cb/ - 1 -

1(~410~3

Accordingly, the present invention provides a pre-
paration for use in curbing the appetite of warm-blooded
animals which comprises an alginic compound and a diphosphonic
compound of the formula:
1 3 2

CH2 - CEI - I 1
COOH COOH P3H2
wherein Rl is hydrogen or methyl and the nontoxic pharma-
cologically acceptable water-soluble salts thereof, as
inhibitor of the precipitation of calcium salts when the
composition is administered to warm-blooded animals.
More particularly, the present invention is directed
to an appetite curbing preparation for warm-blooded animals
comprising
(A) an alginic compound selected from the groups
consisting of alginic acid and the nontoxic pharmacologically
acceptable water-soluble salts thereof, and
~ 3) a substoichiometric amount based on the calcium
ions required to gel said ~lginic compound of a diphosphonic
compound as precipitation inhibitor for calcium ions selected
; from the group consisting of a diphosphonic compound having
the formula
P03H2

CH2 ~ IH ~ I R

COOH COOH P3H2

wherein Rl is hydrogen or methyl and the nontoxic pharma-
cologically acceptable water-soluble salts thereof.
Also, the present invention provides an appetite
curbing composition for a warm-blooded animal consisting essen-


tially of 25% to 50% by weight of the above appetite curbingpreparation and 50~ to 75% by weight of a nontoxic pharma-


~ologically acceptable carrier.
,,,, ~
~- cb/ - 2 -

1041013
In addition, the present invention provides a method
for curbing the appetite of warm-blooded animals comprising ~ :
administering to said animals an anoretically effective amount
of the appetite curbing preparation mentioned above.
Also, the present invention provides an improvement
in a process for dieting, which consists essentially in con-
suming ~during or before a meal) an effective amount of the
appetite curbing preparation mentioned above as an anoretic
material.
It has become apparent that in principle it is
possible to preyent the formation of calcium alginate by add-
ing thereto a strong sequestering agent, for example, nitrilo-
triacetic acid or ethylenediaminetetraacetic acid. However,
the calcium ions are thereby sequestered to such an extent
that they may possibly no longer be available for physiological
processes in the warm-blooded animal. Moreover, the precipi-
tation of the calcium salts can be prevented for a consider-
able period of time by using compounds which have a strong -~
inhibiting effect (threshold effect). In this case, crystalline
growth is probably inhibited to a very great extent by the
incorporation of the inhibitor into seed crystals. Compounds
haying a threshold effect particularly include polyphosphates
haying a chain-like structure and include sequestering agent
phosphonic acids, such as methylphosphonosuccinic acid or 2-
phosphonobutane~l,2,4-tricarboxylic acid. However, condensed
phosphates are not suitable for this purpose since they are
split up by phosphatases in the body to give ineffective
monophosphate. Moreover, tests have shown that, under the
physiological conditions which prevail in the intestinal
tract, the majority of sequestering agent phosphonic acids
are either unsuitable or are not sufficiently effective.
It was therefore surprising that the above-




cb/ h 3 _


., ,

141013

mentioned dicarboxydiphosphonic acids and their nontoxicpharmacologically acceptable water-soluble salts constitute
suitable ingredients for the above preparation. The com-
pounds are diphosphonoalkanedicarboxylic acids selected from
the group consisting of l,l-diphosphonopropane-2,3-dlcarboxylic
acid and 2,2-diphosphonobutane-3,4-dicarboxylic acid, with the
former acid being preferred.
Instead of these acids, it is also possible to use
their nontoxic pharmacologically acceptable, water-soluble
salts, such as the alkali metal salts, for example, sodium
and potassium, and the magnesium salts, and the ammonium and
substituted ammonium salts such as the lower alkylol-ammonium
salts, for example, the mono-, di- or tri- ethylolammonium
salts. It is also possible to use the partial salts, in
which only a proportion of the acidic protons is replaced by
other cations. Partial salts, which produce a pH in the range
~om 6 to 8.5 in aqueous solution, are preferred. Mixtures
of the above-mentioned acids and their salts can also be used.
The proportion of the precipitation inhibitors in
the appetite curbing preparations containing an alginic com-
pound is variable. However, this proportion must be great
enough to inhibit the precipitation of calcium ions in the
intestinal tract. This precipitation is possibly caused by
the presence of calcium hardness (i.e., calcium ions) in the
wate~. Based upon a 10 gm amount of the alginic compound,
about 50 to 200 mg,preferably 100 to 200 mg, of the precipi-
tation inhibitor can be present in compositions of the invention.
This corresp~nds to the weight ratio of l50 to 200):1 for the
alginic compound to the precipitation inhibitor, equivalent
to 1/2% to 2% of the inhibitor on the weight of the alginic
compound. However, for the ressons as stated above, precipi-
tation inhibitor is preferably present in substoichiometric




cb/ ~ - 4 _

- lV~1013

amount based on the calcium required to gel said alginic
compound.
Commercial alginic acid, or its nontoxic pharma-
cologically acceptable water-soluble salts such as the alkali-
metal salts, are suitable as the alginic ingredient. Potassium
alginate or, preferably, sodium alginate can be used as alkali
metal salts. Ammonium alginate can also be used. The pre-
parations can be produced for administration in the form of
tablets, pills or powder and may contain known ingredients
such as sodium bicarbonate or Na2HPO4 as well as binding
agents for the production of tablets. Further additives
which may be present in the appetite curbing compositions
are flavorings, vitamins and sugar/fruit concentrates.
Generally speaking, the appetite curbing composi-
tions according to the invention contain from 25% to 50% by
weight of the alginate-diphosphonic acid preparation, with
the balance up to 100% by weight being the other known ingred-
ients and/or additives mentioned aboye which constitute an
inert nontoxic pharmacologically acceptable carrier.
The appetite curbing compositions are administered
orally to warm-bloQded animals in units which contain an
anoretically effective amount, or about 15 to 70 mg/kg of body
weight ~preferably 25 to 50 mg/kg of body weight~, of the
alginic-diphosphonic acid combination. These dosage units
can be in the form of tablets, pills or powders and are con-
veniently administered by dissolving the tablets, pills or
powders of the combination in a suitable liquid medium such
as water, milk, fruit juice or a carbonated beverage. The
liquid medium contains from 0.5% to 5% by weight of the appetite
' 30 curbing composition, and can be consumed by drinking.
The appetite curbing preparations of the present

invention have the advantage of preventing precipitation
"

cb/ - 5 -

:

13
or excessive sequestering of calcium ions. The ease of digest-
ibility of the anoretic agent is greatly increased, even for
sensitive persons.
The following examples illustrate the present
invention without limiting it in any manner.

EXAMPLE

In order to test the activity of the compositions
containing compounds which might be effective as precipitation
inhibitors, the following experiments were carried out. 600 mg
of sodium alginate was slowly stirred into 50 ml of a solution
of sodium bicarbonate ~Na2HPO4) containing the inhibitor stated
in Table I. After filling up to the final volume, the follow-
ing concentrations were obtained per liter of alginate solution:
6 gm of sodium alginate
0.075 gm of precipitation inhibitor
; 2 gm of HC03 ions
0.1 gm of HPO4 ions
The above concentrations of bicarbonate and hydrogen
phosphate ions were approximately equivalent to the inorganic
components of intestinal juice. The solution had a pH of 8.
As soon as the sodium alginate had homogeneously dissolved,
- 50 ml of 40 dH ~German hardness) hard water was added, so
that the sQlution had a calcium hardness of 20 dH. The
: precipitatlon of calcium alginate became apparent through
~elling or clotting, whlch could readily be observed by
means of deposlts on the walls of the container when the
sample was shaken.
A control sample of the alginic compound was also
mixed with the bicarbonate-hydrogen phosphate solution. The
; 30 results of the control test together with the results of the

test with a composition of the inyention are reported in
Table I. The results of the same tests with comparative
' ~h
- cb/ - 6 -

: ' ;: ' .:
', ' ' ~ ' ~ , ' ' '

1~4~0~3
precipitation inhibitors are reported in Table II. The com-
parative tests clearly indicate that the desired results are
not achieved with other prior art compounds, even though
these do in part have a yery similar sequestering effect.
Table I

ecipitation Inhibitor Results
None ~control) Strong to very strong gelation

l,l-Diphosphonopropane-
2,3-dicarboxylic acid Weak gelation

Table II

Precipitation Inhibitors
tComparative) Results

Methylenediphosphonic
acid Strong to medium strong gelation

Ethane-l,l-diphosphonic
acid Strong to very strong gelation

Propane-1,2,3-tri-
phosphonic acid Strong gelation

Methylphosphonosuccinic
20 acid yery strong gelation

: 2-Phosphonobutane-
1,2,4-tricarboxylic
acid Medium strong gelation

Amino-tris-(methylene- Strong to extremely strong
phosphonic acid) gelation

Dimethylaminomethane-
diphosphonic acid Medium strong to strong gelation

Aminoacetic acid-
N,N-dimethylene-
30 phosphonic acid Very strong gelation

Chlorobenzyl-
diphosphonic acid Strong to very strong gelation

- Ethylenediamine-
tetrakis-~methylene~
phosphonic acid) Strong to yery strong gelation

Hexamethylenediamine-
tetrakis-(methylene-
phosphonic acid) Strong to very strong gelation

Cyclohexanehexa-
carboxylic acid Medium strong to strong gelation



cb/ ~ - 7 -

lV~10~3
EXAMPLE 2

A preparation which was suitable as an appetite
curbing agent was prepared from the following composition
by weight:
64.5% sugar/fruit concentrate
35% sodium alginate

0.5~ of the diphosphonic acid
of Example 1
in the form of the sodium salt.
10 Approximately 6 gm of the anoretic preparation
was placed in a dry glass and filled up with 200 gm of cold
water while being stirred. The drink was imbibed approximately
15 minutes before the reduced meals.
Although the present inventlon has been disclosed
in connection with a few preferred embodiments thereof,
variations and modifications may be resorted to by those
skilled in the art without departing from the principles of
the new invention. All of these variations and modifications
are considered to be within the true spirit and scope of the
present invention as disclosed in the foregoing description
and defined by the appen~ed claims.




':


..~.

,,




~/ - 8 -

' , ~ , .

Representative Drawing

Sorry, the representative drawing for patent document number 1041013 was not found.

Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date 1978-10-24
(45) Issued 1978-10-24
Expired 1995-10-24

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA)
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Description 1994-05-24 8 318
Drawings 1994-05-24 1 6
Claims 1994-05-24 2 49
Abstract 1994-05-24 1 11
Cover Page 1994-05-24 1 21